Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	OrganiGram	Provention Bio	Chinook Therapeutics	Akouos	Odonate Therapeutics
Symbol	NASDAQ:OGI	NASDAQ:PRVB	NASDAQ:KDNY	NASDAQ:AKUS	NASDAQ:ODT
Price Information
Current Price	$2.34	$7.85	$14.78	$14.53	$3.26
52 Week Range	Hold	Buy	Buy	Buy	Hold
MarketRank™
Overall Score	1.6	1.6	1.4	1.6	1.8
Analysis Score	4.2	4.4	3.5	3.4	3.0
Community Score	3.0	2.7	2.9	2.5	2.1
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.8	0.0	1.7	2.5
Earnings & Valuation Score	0.6	0.0	0.6	0.6	1.3
Analyst Ratings
Consensus Recommendation	Hold	Buy	Buy	Buy	Hold
Consensus Price Target	$4.41	$19.75	$30.33	$31.67	$19.33
% Upside from Price Target	88.51% upside	151.59% upside	105.23% upside	117.94% upside	493.05% upside
Trade Information
Market Cap	$603.91 million	$510.17 million	$650.06 million	$490.23 million	$125.46 million
Beta	0.3	3.34	0.26	N/A	0.66
Average Volume	23,663,707	1,368,585	119,731	213,403	3,696,222
Sales & Book Value
Annual Revenue	$64.61 million	N/A	$17.26 million	N/A	N/A
Price / Sales	8.41	N/A	36.29	N/A	N/A
Cashflow	$0.02 per share	N/A	N/A	N/A	N/A
Price / Cash	101.50	N/A	N/A	N/A	N/A
Book Value	$1.04 per share	$1.72 per share	$4.07 per share	N/A	$5.06 per share
Price / Book	2.25	N/A	3.63	N/A	N/A
Profitability
Net Income	$-101,290,000.00	$-43,280,000.00	$-82,370,000.00	N/A	$-111,820,000.00
EPS	($0.08)	($1.06)	($5.15)	N/A	($4.05)
Trailing P/E Ratio	N/A	N/A	N/A	0.00	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-207.26%	N/A	-215.80%	N/A	N/A
Return on Equity (ROE)	-10.00%	-67.66%	-112.72%	N/A	-85.75%
Return on Assets (ROA)	-7.14%	-62.27%	-21.36%	N/A	-71.45%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.17%	N/A	N/A	N/A	N/A
Current Ratio	2.66%	9.23%	11.27%	37.39%	6.68%
Quick Ratio	3.39%	9.23%	11.27%	37.39%	6.68%
Ownership Information
Institutional Ownership Percentage	10.84%	39.42%	N/A	88.70%	96.00%
Insider Ownership Percentage	N/A	14.40%	5.90%	N/A	48.90%
Miscellaneous
Employees	516	59	43	54	134
Shares Outstanding	232.27 million	63.38 million	42.38 million	34.40 million	38.60 million
Next Earnings Date	7/20/2021 (Estimated)	5/6/2021 (Estimated)	5/3/2021 (Estimated)	7/5/2021 (Estimated)	4/27/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable	Not Optionable

Source	Headline
	Odonate Therapeutics, Inc. (NASDAQ:ODT) Receives Average Rating of "Hold" from Analysts americanbankingnews.com - April 17 at 10:53 AM
	Odonate Therapeutics, Inc. (NASDAQ:ODT) Sees Significant Decrease in Short Interest americanbankingnews.com - April 14 at 11:56 AM
	Odonate Therapeutics (ODT) is Oversold: Can It Recover? finance.yahoo.com - April 9 at 9:59 AM
	Odonate Therapeutics Target of Unusually Large Options Trading (NASDAQ:ODT) americanbankingnews.com - April 7 at 2:18 PM
	Odonate Therapeutics, Inc. (NASDAQ:ODT) Expected to Announce Earnings of -$0.85 Per Share americanbankingnews.com - April 6 at 8:12 PM
	Odonate Therapeutics, Inc. (NASDAQ:ODT) Stock Forecast for 2021: Bullish Signs Point to $4 per Share marketingsentinel.com - March 29 at 9:31 AM
	Do Options Traders Know Something About Odonate Therapeutics (ODT) Stock We Don't? finance.yahoo.com - March 24 at 10:19 AM
	Odonate Therapeutics stock plummets toward record low after plan to 'wind down' operations finance.yahoo.com - March 22 at 6:11 PM
	Why Odonate, Marker Therapeutics and Dyadic Are Moving Monday msn.com - March 22 at 1:10 PM
	Odonate Therapeutics To Wind Down Operations - Quick Facts nasdaq.com - March 22 at 1:10 PM
	Why Odonate Therapeutics Stock Is Crashing Today finance.yahoo.com - March 22 at 1:10 PM
	Odonate Therapeutics Announces Discontinuation of Development of Tesetaxel finance.yahoo.com - March 22 at 8:10 AM
	What Will Odonate Therapeutics, Inc. (NASDAQ:ODT) Be Like After It Drops -74.42% From Its Highs? marketingsentinel.com - February 7 at 6:39 PM
	Revisiting Odonate Therapeutics seekingalpha.com - February 2 at 8:09 PM
	Trade Alert: The Independent Director Of Odonate Therapeutics, Inc. (NASDAQ:ODT), Craig Johnson, Has Just Spent US$51k Buying A Few More Shares nasdaq.com - January 2 at 12:40 PM
	3 Beaten-Down Stocks Insiders Scooped Up as 2020 Ended finance.yahoo.com - January 2 at 7:40 AM
	Thinking about buying stock in Gevo Inc, Inovio Pharmaceuticals, Odonate Therapeutics, Cocrystal Pharma, or Vuzix Corp? marketwatch.com - December 24 at 12:26 PM
	Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS) finance.yahoo.com - December 11 at 12:28 PM
	Odonate Therapeutics to Host Virtual Investor and Analyst Event on December 11, 2020 finance.yahoo.com - December 1 at 9:07 AM
	ODT Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Odonate Therapeutics, Inc. Shareholders With Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: November 16, 2020 finance.yahoo.com - November 16 at 6:56 PM
	ODT Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Odonate Therapeutics, Inc. Shareholders With Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline ... businesswire.com - November 16 at 1:56 PM
	FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm finance.yahoo.com - November 16 at 1:56 PM
	FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm finance.yahoo.com - November 16 at 1:56 PM
	DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm finance.yahoo.com - November 15 at 1:50 PM
	FINAL DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action – ODT feeds.benzinga.com - November 15 at 1:07 PM

Date	Company	Brokerage	Action
4/20/2021	OrganiGram	CIBC	Reiterated Rating
4/15/2021	OrganiGram	Stifel Nicolaus	Boost Price Target
4/14/2021	OrganiGram	Raymond James	Lower Price Target
4/14/2021	OrganiGram	Canaccord Genuity	Boost Price Target
4/13/2021	OrganiGram	Alliance Global Partners	Lower Price Target
4/8/2021	OrganiGram	BMO Capital Markets	Upgrade
3/11/2021	OrganiGram	Cantor Fitzgerald	Reiterated Rating
8/10/2020	OrganiGram	Jefferies Financial Group	Reiterated Rating
4/19/2021	Provention Bio	HC Wainwright	Reiterated Rating
4/19/2021	Provention Bio	Chardan Capital	Lower Price Target
4/15/2021	Provention Bio	SVB Leerink	Lower Price Target
4/15/2021	Provention Bio	Royal Bank of Canada	Reiterated Rating
4/9/2021	Provention Bio	Oppenheimer	Reiterated Rating
3/22/2021	Chinook Therapeutics	Bloom Burton	Reiterated Rating
1/6/2021	Chinook Therapeutics	Wedbush	Initiated Coverage
11/2/2020	Chinook Therapeutics	Evercore ISI	Initiated Coverage
10/6/2020	Chinook Therapeutics	William Blair	Reiterated Rating
3/30/2021	Akouos	Bank of America	Downgrade
7/21/2020	Akouos	BTIG Research	Initiated Coverage
7/21/2020	Akouos	Piper Sandler	Initiated Coverage
7/21/2020	Akouos	Cowen	Initiated Coverage
3/22/2021	Odonate Therapeutics	Lifesci Capital	Downgrade
3/22/2021	Odonate Therapeutics	The Goldman Sachs Group	Lower Price Target
9/9/2020	Odonate Therapeutics	Ci Capital	Reiterated Rating

(Data available from 4/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources